Table I.

Baseline developmental and behavioral outcome measures in participants who completed the study

	Levodopa (n=29)	Placebo (n=26)	p value
BSID-III Age Equivalent in months: Mean (± SD)
Cognitive scale	19.0 (± 7.9)	18.3 (± 6.4)	0.75
Receptive Communication	16.0 (± 8.5)	15.0 (± 8.2)	0.64
Expressive Communication	9.7 (± 4.0)	8.7 (± 3.8)	0.32
Fine Motor	17.8 (± 10.4)	15.7 (± 7.8)	0.40
Gross Motor	16.8 (± 6.0)*	15.8 (± 5.0)	0.52
VABS-II Standard Scores: Mean (± SD)
Communication	48.9 (± 9.1)	46.9 (± 7.4)	0.39
Daily Living Skills	53.2 (± 10.2)	50.3 (± 10.9)	0.33
Socialization	57.5 (± 10.8)	54.9 (± 10.9)	0.37
Motor Skills	55.5 (± 5.1)*	53.9 (± 7.1)	0.33
Adaptive Behavior Composite	51.7 (± 9.3)	49.8 (± 8.3)	0.44
ABC Raw scores: Mean (± SD)	n=28	n=24
Irritability	9.1 (± 9.3)	4.8 (± 4.6)	0.05
Lethargy	4.7 (± 4.6)	2.7 (± 3.3)	0.07
Stereotypy	5.1 (± 3.7)	3.0 (± 3.6)	0.04
Hyperactivity	19.5 (± 12.2)	15.5 (± 10.8)	0.22
Tremors in last 3 months	16 (55%)	15 (58%)	0.85

^*n=28 in the Levodopa group

Abbreviations: BSID-III – Bayley Scales of Infant and Toddler Development, Third Edition; VABS-II – Vineland Adaptive Behavior Scales, Second Edition; ABC – Aberrant Behavior Checklist, Community Version